Cantor Fitzgerald launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “overweight” rating and 12-month price target of $5. The stock closed at $2.76 on Sept. 22. Solid is using its gene therapy platform to...
Raymond James upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “strong buy” from “outperform” with a price target of $20.00, after pricing-in the TULSA-PRO system’s 2025 sales inflection. At mid-day on September 18...
Alliance Global Partners initiated coverage of Nano-X Imaging (NASDAQ:NNOX) with a “buy” rating and price target of $14.50. The stock closed at $7.66 on Sept. 7. “Nano-X’s novel digital X-ray source has the potential to...
Cantor Fitzgerald upgraded Ardelyx (NASDAQ:ARDX) to “overweight” from “neutral” and doubled its price target to $10 from $5, citing an upcoming PDUFA date of Oct. 17 for flagship drug, Xphozah, and higher sales...
Alliance Global Partners initiated coverage of Aspira Women’s Health (NASDAQ:AWH) with a “buy” rating and price target of $5.60. The stock closed at $2.76 on Aug. 21. Aspira Women’s Health’s proprietary...
Cantor Fitzgerald downgraded Aravive (NASDAQ:ARAV) to “neutral” from “overweight” and slashed its price target to 25 cents from $18 after the company indicated it might be forced to cease operations. The stock closed at...
Leerink Partners raised its price target for Centessa Pharmaceuticals (NASDAQ:CNTA) to $11 from $6, and reiterated an “outperform” rating, citing an improved outlook for its pipeline. The stock closed at $6.62 on Aug...
Leerink Partners initiated coverage of Turnstone Biologics (NASDAQ:TSBX) with a “market perform” rating and $13 price target. The stock closed at $11.73 on Aug. 14. “We see potential in Turnstone’s selected tumor...
Ladenburg Thalmann downgraded Salarius Pharmaceuticals (NASDAQ:SLRX) to “neutral” from “buy” and removed its price target after the company disclosed it is exploring strategic alternatives and implement cost-cutting...
Leerink Partners upgraded Quanterix (NASDAQ:QTRX) to “outperform” from “market perform” and raised its price target to $30 from $25, citing strong evidence for its assays redevelopment effort. Analyst Puneet Souda...